Format

Send to

Choose Destination
J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):299-306. doi: 10.1097/QAI.0b013e3182a2123a.

HIV disease progression in the first year after delivery among African women followed in the HPTN 046 clinical trial.

Author information

1
*Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD; †Fred Hutchinson Cancer Research Center, Seattle, WA; ‡Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA; §University of Zimbabwe College of Medicine, Harare, Zimbabwe; ‖Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa; ¶Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda; #Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; **Harvard School of Public Health, Boston, MA; ††Family Health International, Research Triangle Park, Chapel Hill, NC; ‡‡Johns Hopkins Medical Institutes, Baltimore, MD; §§National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD; ‖‖Maternal Adolescent and Child Health, University of the Witwatersrand, Johannesburg, South Africa, and ¶¶Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Seattle, WA.

Abstract

BACKGROUND:

Starting lifelong antiretroviral therapy (ART) in HIV-infected pregnant women may decrease HIV progression and transmission, but adherence after delivery may be difficult, especially for asymptomatic women. We evaluated disease progression among HIV-infected women not on ART with CD4⁺ lymphocyte counts above 200 cells per microliter at delivery.

METHODS:

We analyzed risk of death, progression to AIDS (stage IV or CD4 < 200 cells per microliter), or to CD4⁺ count <350 1 year after delivery among postpartum women enrolled to a prevention of breastfeeding transmission trial using the Kaplan-Meier method. In the primary analysis, women were censored if ART was initiated.

RESULTS:

Among 1285 women who were not WHO stage IV or less at 6 weeks postpartum, 49 (4.3%) progressed to stage IV/CD4 <200 cells per microliter or death by 1 year. Progression to CD4 <200 cells per microliter or death occurred among 16 (4.3%) of 441 women with CD4 count of 350-549 cells per microliter and 10 (1.6%) of 713 with CD4 counts >550 cells per microliter at delivery. CD4 <350 cells per microliter by 12 months postpartum occurred among 116 (37.0%) of 350 women with CD4 count 400-549 cells per microliter and 48 (7.4%) of 713 with CD4 count >550 cells per microliter at delivery.

CONCLUSIONS:

Progression to AIDS or CD4 count <350 cells per microliter is uncommon through 1 year postpartum for women with CD4 counts over 550 cells per microliter at delivery, but occurred in over one third of those with CD4 counts under 550 cells per microliter. ART should be continued after delivery or breastfeeding among women with CD4 counts <550 cells per microliter if follow-up and antiretroviral adherence can be maintained.

PMID:
23846568
PMCID:
PMC3800257
DOI:
10.1097/QAI.0b013e3182a2123a
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center